Association of British Clinical Diabetologists

Previous/current nationwide audits

 
Home Live ABCD audits of new therapies and devices All ABCD nationwide audits Future audits of new therapies ABCD worldwide audits
     

Above - centres contributing to the ABCD nationwde exenatide (left) and liraglutide (rigtht) audits – click to enlarge

 

Above: In real clinic practice in the UK, patients treated with exenatide or liraglutide had far worse glycaemic control and were much heavier than patients treated in clinical trials  – click to enlarge

 

Above: Key messages from the paper on pancreatitis in the ABCD nationwide liraglutide audit. They illustrate the extent to which the ABCD audits can contribute to debates on important clinical issues – click to enlarge

 

Above: Though the combination of exenatide and insulin was not licensed at the time of the ABCD nationwide exenatide audit, many contributors to the audit found benefits from the combination  – click to enlarge

 

Above: In both the ABCD nationwide exenatide and liraglutide audits, it was found that whilst about 60% patients achieved improvement in both HbA1c and weight, less than half of these achieved this to the criteria levels set by NICE. Many patients achieved considerable HbA1c reduction but not much weight reduction, whilst many others achieved considerable weight reduction but not much HBA1c reductions - click to enlarge

 

Above: Liraglutide – coming off insulin, improving control, losing weight and “never felt so good” – click to enlarge

The history of the ABCD nationwide audit programme

The establishment of the ABCD nationwide audit programme on N3 - the latest version of NHSnet, represents the culmination of a national audit programme which has been evolving and becoming increasingly larger and more sophisticated since 2004. Below the national audits are listed in reverse chronological order:

2017 - Nationwide IDegLira audit
The nationwide IDegLira® audit launched in April 2017. All users of IDegLira, liraglutide and degludec are invited to join the audit. Click here for more information and to join the audit.

2017 - Nationwide empagliflozin audit
The nationwide Invokana® audit launched in March 2017. All users of empagliflozin are invited to join the audit. Click here for more information and to join the audit.

2016 - Nationwide canagliflozin audit
The nationwide Invokana® audit launched in January 2016. All users of canagliflozin are invited to join the audit. Click here for more information and to join the audit.

2014 - Nationwide insulin degludec audit
The nationwide Tresiba® audit launched in November 2014. All users of insulin degludec are invited to join the audit. Click here for more information and to join the audit.

2014 - Nationwide dapagliflozin audit
The nationwide Forxiga® audit launched in October 2014. All users of dapagliflozin are invited to join the audit. Click here for more information and to join the audit.

2014 - Nationwide exenatide QW audit
The nationwide Bydureon® audit launched in April 2014. All users of exenatide QW are invited to join the audit. Click here for more information and to join the audit.

2014 - National audit of DKA management
This audit aims to assess diabetic ketoacidosis management (DKA) management across the UK following the introduction of the latest version of the JBDS DKA guideline (see guidelines 2a and 2b ). For more information click here.

2012-2014 - IDOP and ABCD care homes audit
The Institute of Diabetes for Older People (IDOP) in association with ABCD has led a national stakeholder audit of diabetes care in care homes. Responses from more than 2000 care homes in England revealed important gaps in screening for diabetes, hypoglycaemia care, and the training and education of care staff in the area of diabetes. The results of this audit have been passed to the Care Quality Commission to assist them in developing inspection processes for care homes.  The report, launched in June, 2014, is available on both the IDOP and ABCD websites.

2009-2014 - Nationwide liraglutide audit - ongoing since 2009
The ABCD nationwide liraglutide audit is ongoing and now has over 6000 patients. There have been several presentations at national and international meetings and there are papers published and being written. The audit tool was upgraded in 2012 to become secure online/web-based. All users of liraglutide are invited to join the audit.

2009-2014 - ABCD Scottish audit of inpatient diabetes care - ongoing since 2009
An audit of Inpatient Diabetes Care across NHS Lothian: The effectiveness of the use of information technology, the Scottish Patient Safety Programme and ‘Think Glucose’.

2011-2013 - ABCD/JDRF/Diabetes UK Insulin Pump Audit
 The joint ABCD/JDRF/Diabetes UK Insulin Pump Audit for the UK surveyed diabetes centres in the UK, to establish basic data on numbers and type of insulin pump starts and follow up, and availability and use of CGMS. The audit was published in May, 2013, and revealed that the proportion of people in the UK who live with type 1 diabetes and use a pump. Publication was accompanied by a press release from JDRF and Diabetes UK, giving their reaction to the audit’s findings and headlined “UK lagging behind Europe for use of insulin pumps”.

2008-2011 - Nationwide exenatide audit
The ABCD nationwide exenatide audit represented a landmark in that it attracted so many contributors and hence data on a large number of patients. 6717 patients (2007-2009), 315 contributors, 126 centres. Several papers are now published with more still being written and there have been many presentations at national and international meetings.

2007 - Nationwide exubera audit
This audit of the inhalable insulin exubera was launched in 2007 but was never completed because exubera was taken off the market.

2005-2006 Nationwide audit of glitazone use with insulin
A nationwide audits undertaken in 2005 and presented as a poster at the ABCD meeting in Glasgow in 2006. The audit found that in extreme insulin resistance some, but not all, patients responded to the combination.

2005-2006 - Nationwide audit of triple OHA use in insulin avoidance
A nationwide audits undertaken in 2005 and presented as a poster at the ABCD meeting in Glasgow in 2006. The audit demonstrated that the addition of glitazones to metformin and sulphonylureas was often very effective and allowed insulin to be avoided or postponed.

2005 - Nationwide audit of gestational diabetes screening
For this audit questionnaires were sent to all ABCD members asking them to describe how in their locality patients were screened for GDM, the diagnostic criteria and subsequent management and clinical targets.  The findings were published in QJM in 2008 and showed that standards for GDM screening and management vary significantly across the UK..

2004 - Nationwide audit of glargine in pregnancy
This audit charted the outcomes on 109 babies from 115 women treated with glargine insulin during pregnancy. The findings were published in Diabetic Medicine in 2008 and suggested that the use of glargine in Type 1 diabetes during pregnancy was not associated with any unexpected adverse maternal or fetal outcome.

   Main ABCD homepage

ABCD canagliflozin audit

ABCD dapagliflozin audit

ABCD empagliflozin audit

ABCD FreeStyle Libre audit 

ABCD exenatide QW audit

ABCD IDegLira audit

ABCD degludec audit

ABCD liraglutide audit

ABCD exenatide audit

ABCD worldwide audits

Endobarrier worldwide registry

Contact us

     

Working to support high quality diabetes care in the UK